Yifan Li

PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer

The aim of this study was to determine the poly (ADP-ribose) polymerase inhibitors (PARPis) response and outcome of ovarian cancer (OC) patients with BRCA1/2 germline mutation and a history of breast cancer (BC). Thirty-nine OC patients with BRCA1/2 germline mutation and a history of BC were included. The clinicopathological characteristics, PARPis response and prognosis were analyzed. The median interval from BC to OC diagnosis was 115.3 months (range=6.4-310.1). A total of 38 patients (38/39, 97.4%) received platinum-based chemotherapy after surgical removal. The majority of these patients were reported to be platinum sensitive (92.1%, 35/38). 21 patients (53.8%) received PARPis treatment with 16 patients (76.2%) for maintenance treatment and 5 patients (5/21, 23.8%) for salvage treatment. The median duration for PARPis maintenance and salvage treatment was 14.9 months (range=2.0-56.9) and 8.2 months (range=5.2-20.7), respectively. In the entire cohort, 5-year progression-free survival (PFS) and overall survival (OS) rate was 33.1% and 78.9%, respectively. Patients with BRCA1 mutation had a non-significantly worse 5-year PFS (28.6% vs. 45.8%, p=0.346) and 5-year OS (76.9% vs. 83.3%, p=0.426) than those with BRCA2 mutation. In patients with stage III-IV (n=31), first line PARPis maintenance treatment associated with a non-significantly better PFS (median PFS: NR vs. 22.4 months; 5-year PFS: 64.3% vs. 21.9%, p=0.096). The current study shows that these patients may have a good response to platinum-based chemotherapy and a favorable survival. And these patients can benefit from PARPis treatment and will likely be suitable candidates for PARPis.

Feasibility and Acceptability of Pay-it-forward in Increasing Uptake of HPV Vaccination among 15- to 18-Year-Old Girls in China: Pilot RCT Results

Abstract China has a low human papillomavirus (HPV) vaccination rate due to limited public funding and mistrust in domestic vaccines. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary effectiveness of an innovative pay-it-forward strategy to improve HPV vaccine uptake among adolescent girls. Conducted at a community health center in Western China (January 4–February 18, 2022), the study recruited 100 adolescent girls (ages 15–18 years) with no prior HPV vaccination. Participants were randomly assigned to either the standard-of-care arm (self-paid vaccines, n = 50) or the pay-it-forward arm (subsidized vaccines, handwritten postcards, and the opportunity to donate and/or write postcards, n = 50). Feasibility was assessed through recruitment, retention, and questionnaire completion rates. Acceptability and feasibility were measured using a standard scale. Preliminary effectiveness was evaluated by first-dose vaccination rate. Of 109 screened participants, 100 were eligible to participate (91.7%). The retention rate was 100% in both arms. The questionnaire completion rate was 98% (49/50) in the pay-it-forward arm and 82% (41/50) in the standard-of-care arm. Most participants self-reported that the strategy was feasible (97.6%, 41/42) and acceptable (90.5%, 38/42). Ninety-seven percent (97/100) of participants made vaccination appointments. The first-dose HPV vaccine uptake rate was 98% (49/50) in the pay-it-forward arm and 82% (41/50) in the standard-of-care arm (P < 0.05). No serious adverse events were identified. The pay-it-forward strategy was feasible and acceptable and showed preliminary effectiveness in increasing HPV vaccination uptake. Further refinement and population-based recruitment are needed to better reflect local contexts and enhance the generalizability of the formal trial. Prevention Relevance: The results of this pilot study demonstrate that the pay-it-forward strategy is both feasible and acceptable in increasing HPV vaccine uptake among 15- to 18-year-old girls. The future use of this strategy holds promise as an effective approach to enhance HPV vaccination rates that will eventually lead to a reduction in cervical cancer incidence.